Use of symmetric IgG and composition thereof in preparing drugs for treating and preventing tumors
A composition and tumor technology, applied in the field of tumor immunotherapy drugs, can solve problems such as the launch of mature drugs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
experiment example 1
[0046] Experimental example 1: anti-tumor effect of symmetrical IgG
[0047] Human IgG is divided into asymmetric IgG (Asy IgG) and symmetric IgG (Sy IgG) by ConA adsorption method, and purified by rProtein G, the specific method is as follows:
[0048] Human IgG flows through the ConA column by gravity, and ConA can be combined with mannose sugars to adsorb glycosylated asymmetric IgG (Asy IgG), while non-Fab glycosylated symmetrical IgG (Sy IgG) flows out The column collects concentrated non-glycosylated symmetrical IgG (Sy IgG). Wash the column with balanced salt solution to remove residual Sy IgG, then use α-methylmannose solution to competitively bind ConA, so that the glycosylated asymmetric IgG (Asy IgG) is separated from ConA, flows out of the column, and is collected and concentrated separately to obtain Asy IgG. In order to prevent residual ConA in the separated Asy IgG and Sy IgG, we pass Asy IgG and Sy IgG through the rProtein G column respectively, both Asy IgG ...
experiment example 2
[0052] Experimental Example 2: Clinical Trial
[0053] A 63-year-old male patient with advanced squamous cell carcinoma of the lung, whose disease was still not under control after surgery, radiotherapy and chemotherapy, the doctor judged that the patient's expected survival period was 3 months, the patient voluntarily used the above symmetric IgG immunotherapy, Intravenous infusion has been used for 18 months so far, the condition has not deteriorated, the patient is still alive, and no side effects have been found.
[0054] Another patient with advanced esophageal cancer (squamous cell carcinoma), a 56-year-old male, had lung metastases, and the cancer could not be controlled after radiotherapy and chemotherapy. The doctor expected the patient's survival to be less than 3 months. Under the strong request, the above immunotherapy was used through intravenous infusion. So far, the patient has survived for 15 months without any further tumor development and no side effects.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com